Sandbox Reserved 825: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
|||
| Line 58: | Line 58: | ||
Other molecules like the novel class inhibitor '''HTS-1''' (4-[6-{[(1S,2R)-2-(benzyloxy)cyclopentyl]acety}-4-(2-thienyl)pyridin-2-yl]-4-oxobutanoic acid) | Other molecules like the novel class inhibitor '''HTS-1''' (4-[6-{[(1S,2R)-2-(benzyloxy)cyclopentyl]acety}-4-(2-thienyl)pyridin-2-yl]-4-oxobutanoic acid) | ||
are also capable of inhibiting the kinase activity of mTOR by partially occupying the binding site for phosphatidic acid. | are also capable of inhibiting the kinase activity of mTOR by partially occupying the binding site for phosphatidic acid. <br /> | ||
There are <scene name='56/568023/Hts-1_binding_residues/2'>ten</scene> residues at the FRB domain that are predominantly involved in HTS-1 binding | There are <scene name='56/568023/Hts-1_binding_residues/2'>ten</scene> residues at the FRB domain that are predominantly involved in HTS-1 binding | ||
(actively: E2032, S2035, Y2038, F2039, T2098, W2101, Y2105, F2108, passively: H2028, L2031). <br /> | (actively: E2032, S2035, Y2038, F2039, T2098, W2101, Y2105, F2108, passively: H2028, L2031). <br /> | ||
